5 Key Takeaways

• 1

  Nordic Pharma has launched Lacrifill®, a new therapy for dry eye, in the European market following CE mark approval in 2025.

• 2

  Lacrifill® is a cross-linked hyaluronic acid gel that temporarily blocks tear drainage to enhance tear film preservation.

• 3

  The gel provides a full fill of the canalicular system, offering long-lasting effects for up to six months.

• 4

  Dry eye disease affects up to 30% of the European population and poses challenges for patients undergoing ocular surgeries.

• 5

  Lacrifill® aims to optimize ocular surface health pre-and post-operatively, improving surgical outcomes and patient satisfaction.